KDM1A inhibitors for the treatment of disease
US11230534B2 · kind B2 · utility
3Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 1, 2019 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Nov 1, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.